Skip to main content
News > News > Timothy P. Cripe, MD, PhD, Appointed To Open Therapeutics Science Directorate

Timothy P. Cripe, MD, PhD, Appointed To Open Therapeutics Science Directorate

Dr. Cripe will advise on unique and innovative therapeutic product development

CINCINNATI, OH. – May 8, 2014 – Microbial Robotics is a life science biotechnology firm.  The Company uses synthetic biology tools in an evolutionary engineering approach to develop bacterial robots, or BactoBotsToday, the Company announced the appointment of Dr. Tim Cripe to its Scientific Directorate.

The Company is developing unique therapeutic BactoBots and ViruBots.  Dr. Cripe’s extensive oncology, hematology, and oncolytic virus expertise will provide important guidance for unique product developments directed to clinical applications.

Jason E. Barkeloo, CEO stated, “Dr. Cripe’s clinical and research accomplishments are well recognized.  The Company is fortunate to have attracted his guidance and expertise for immunological, viral, and oncology product development.”

Dr. Cripe is the Chief of the Hematology, Oncology, and Bone Marrow Transplantation at Nationwide Children’s Hospital and a faculty member of The Ohio State University College of Medicine.

Formally, he was the Medical co-Director of the Office for Clinical and Translational Research.  Dr. Cripe was the Founding Director of the Comprehensive Musculoskeletal Tumor Program at Cincinnati Children’s Hospital Medical Center.

At the University of Cincinnati, Dr. Cripe was a Pediatrics Professor and directed Pilots and Collaborative Studies in the Center for Clinical and Translational Science and Training.

Barkeloo added, “We are focused upon creating innovative products and intellectual property.  Dr. Cripe’s leadership will help Microbial Robotics reduce product development risks.  That is, end-user applications will be informed from the outset of product development by Tim’s expertise.”

Dr. Cripe finished, “Harnessing millions of years of biologic evolution by redirecting bacteria and viruses to solve human problems is an exciting venture with enormous potential. I am thrilled to be associated with the outstanding team at Microbial Robotics.”

More on Dr. Cripe is at:


About Microbial Robotics

An early developer in the emerging synthetic biology industry, Microbial Robotics is headquartered in Cincinnati, Ohio (USA).  It has operations in Cincinnati, OH and Covington, KY.  The Company specializes in identifying markets for developing and deploying BactoBots™ and ViruBots™; microscopic organism-based robots that produce, build, sense, and perform functions.

The Company’s products are protected by a proprietary genetics rights management (GeRM™) key system.  The GeRM system is a consumable additive that prevents the BactoBots against theft or release.  The GeRM key consumable enables the Company to gain revenues from licensing the manufacture and distribution of its BactoBots.

Once Bacterial Robotics develops a BactoBot or ViruBot, it creates a go-to-market subsidiary to launch the product.  Pilus Energy was the Company’s first subsidiary, a wastewater-to-value company.  That subsidiary was merged with Tauriga Sciences, Inc. (OTCQB: TAUG) in January 2014.


Jason E. Barkeloo



Twitter:  @BactoBot at


Our Effort

Open Therapeutics is a major backer of open science and open access efforts.

Open Therapeutics freely provides to science, technology, engineering, and math (STEM) scientists, or another other seriously interested persons, intellectual properties (patents, etc.), grant funding, lab equipment, document development tools, and preprint server in a collaboration platform (Therapoid™).

When the researchers advance the intellectual properties, s/he gains ScienceCoins™; a blockchain-based cryptocurrency.